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Abstract
Objective: The objective of this evidence based medicine review is to determine whether or not
Botulinum Toxin A is safe and effective for the treatment of trigeminal neuralgia in adults.
Study Design: Three double blind, randomized controlled trials were reviewed and selected
based on their relevance to the clinical question and their inclusion of patient oriented outcomes
(POEMS).
Data Sources: Each study was obtained by searching NCBI and PubMed database.
Outcome measures: The outcomes were measured using the Visual Analog Scale (VAS), Quality
of Life (QoL), Patient Global Impression of Change Scale (PGIC), Last Observation Carried
Forward (LOCF), and detected adverse effects.
Results: The results Shehata et al. study showed that the VAS and LOCF showed significant
decrease in daily pain, use of acute medications, daily paroxysms, and increase in QoL using
Botulinum Toxin A vs. normal saline. These results were shown by pain had a decrease by 6.5
with Botulinum Toxin A vs. 0.3 with normal saline, paroxysms with a score of 0.88 to 7.12,
acute medications with a score of 3.69 to 5.71, and QoL with a score of 8.35 to 9.65, and these
all had p values of <0.0001 and CO of 95% respectively utilizing simple descriptive analysis,
ANCOVA model, and Pearson correlation coefficient. This study also showed adverse effects of
facial asymmetry utilizing ARI and NNH which showed for every 3 participants, 1 participant
3
experienced facial asymmetry
. The results of Wu et al. study showed that the VAS and PGIC
showed significant decrease in daily pain and daily paroxysms. By utilizing the Fisher exact test,
RBI, ABI, and NNT, PGIC showed for every 3 participants, 1 participant experienced
improvement and p values of <0.05 and by utilizing the Wilcoxin rank sum test, VAS showed
improvement with daily pain and paroxysms with a p value <0.05. This study also showed
adverse effects of facial asymmetry utilizing ARI and NNH which showed for every 2
4
participants, 1 participant experienced facial asymmetry
. The Zuniga et al. showed that the VAS
showed significant decrease in daily pain and paroxysms. Utilizing the Ttest and paired ttest,
VAS showed improvement with pain and paroxysms with a p value of <0.001. This study also
showed adverse effects of facial asymmetry utilizing ARI and NNH which showed for every 10
5
participants, 1 participant experienced facial asymmetry
.
Conclusions: All three RCTs demonstrated positive outcomes with Botulinum Toxin A in the
treatment of trigeminal neuralgia with low risk of detected adverse effects.
Keywords: trigeminal neuralgia, Botulinum Toxin A
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Introduction
Trigeminal neuralgia is a chronic pain condition caused by inflammation of the
trigeminal nerve which is the most widely distributed nerves in the head. This nerve has three
branches which supplies sensation to the scalp, eyes, eyelids, forehead, cheeks, jaw, lips, teeth,
and gums. Trigeminal neuralgia affects 150,000 people every year where it can affect any age
group. Trigeminal neuralgia can be triggered by just any daily task like touching one’s face,
washing one’s face, shaving, brushing one’s teeth, blowing one’s nose, drinking hot/cold
beverages, applying makeup, smiling and even talking which all these things people do on a
1
daily basis so it can really have a negative impact on a patients quality of life
. About 8,000

patients with trigeminal neuralgia undergo surgical intervention each year which costs are
estimated over $100 million per year. The exact cause of TN is unknown. Trigeminal neuralgia
could be caused by many things. Some are compression of the nerve by a blood vessel exiting
the brain stem, multiple sclerosis, trauma, stroke, tumor on the nerve, and/or rarely arteriovenous
malformation. There is no exact cure of trigeminal neuralgia but there are many treatments
which vary from oral medications to surgical intervention to help decrease symptoms and pain.
The usual methods used to treat trigeminal neuralgia are anticonvulsant medications (i.e.
carbamazepine, phenytoin, gabapentin, topiramate), microvascular decompression, percutaneous
stereotactic rhizotomy, percutaneous glycerol rhizotomy, percutaneous balloon compression,
2
stereotactic radiosurgery, motor cortex stimulation
. This method of treatment (Botulinum Toxin

A) is being proposed because the treatment options mentioned above all can play a role in

treating trigeminal neuralgia, but most of the treatment options consist of surgical intervention
which are invasive and not guaranteed effective and the use of Botulinum Toxin A has been
shown to be effective in the treatment of trigeminal neuralgia.
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Objective
The objective of this evidence based medicine review is to determine whether or not
Botulinum Toxin A is safe and effective for the treatment of trigeminal neuralgia in adults.
Methods
The population consists of men and women over 21 years of age with a diagnosis of
trigeminal neuralgia. The intervention is Botulinum Toxin A and the comparison is normal
saline. The outcomes consist of the reduction of daily pain of trigeminal neuralgia using
Botulinum Toxin A, daily paroxysms of trigeminal neuralgia using Botulinum Toxin A, and
adverse effects of Botulinum Toxin A for the treatment of trigeminal neuralgia. The studies that
are included in this review consist of three randomized controlled trials (RCTs). The keywords
used in the searches were “Botulinum Toxin A” and “trigeminal neuralgia”. All articles were
published in English. All articles were published in peer reviewed journals and found via NCBI
and PubMed. The articles were selected based on relevance and that the outcomes of the studies
mattered to the patients (POEMS). The inclusion criteria consisted of studies that were RCTs
published after 1996 and topics not used by prior students in our program, and patients over the
age of 21 with a diagnosis of trigeminal neuralgia. The exclusion criteria consisted of patients
who responded to usual medical to usual medical therapy, pregnant women, patients with history

of trigeminal neuralgia from secondary causes, or hypersensitivity reaction to Botulinum Toxin
A. The summary of statistics reported or used were pvalue, RRI, RBI, ABI, ARI, NNH, NNT.

Table of demographics and characteristics of included studies (Table 1)
Study

Type

#
Pts

Age
(yrs)

Inclusion criteria

Exclusion criteria

W/D

Interventions

Shehata2
013
(1)

RCT

20

2772

Subjects had
idiopathic TN
according to HIS
criteria, all patients
elicited sensory
stimulation in
different skin area,
and failure in
reduction of pain
last 3 months

Patients who responded
to medical treatments,
pregnant women,
symptomatic trigeminal
neuralgia (abnormal
neurological
examination or
demonstrable structural
lesion by MRI),
patients with possibility
of lack of coherence
during follow up

0

Botulinum Toxin
A 100 U in 2mL
preservative free
normal saline
resulting in a
concentration of
5 u/1mL vs.
Visually matched
placebo 2 mL of
0.9% NaCl saline

Wu 2012
(2)

RCT

42

3088

Failure of recent
treatment for TN at
baseline and
understanding the
information given
relative to the trial,
particularly with
regard to possible
complications such
as transient facial
weakness

Pts with any medical
condition or use of
agent that puts them at
increased risk if
exposed to Botulinum
Toxin A or skin
infection at injection
site, women of child
bearing age, nursing, or
planning pregnancy

2

Botulinum Toxin
A 75U/ 1.5 mL
(saline) vs.
Visually matched
placebo 1.5 mL
of normal saline

Zuniga
2013
(3)

RCT

36

4293

Men and women
greater than 18 y/o
with diagnosis of
TN, brain MRI r/o
secondary causes,
subjects who had
not responded to
usual treatment
prior

Subjects with hx of TN
from secondary causes,
who responded to usual
treatment, change in
their medications 2
months before study,
women of child bearing
potential,
hypersensitivity to
Botulinum Toxin A, or
concomitant conditions
where invasive
procedures are
contraindicated

0

Botulinum Toxin
A 50U/ 1mL vs.
Visually matched
placebo 0.9%
saline 1mL
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Outcomes Measured
The outcomes were measured by Visual Analog Scale (VAS), Quality of Life (QoL)
,
Patient Global
Impression of Change Scale (PGIC)
,
Last Observation Carried Forward (LOCF)
,
Detected adverse
effects.

Results
All three articles reviewed were randomized controlled trials and all assessed the efficacy
of Botulinum Toxin A in the treatment of trigeminal neuralgia. All three studies used a placebo
of normal saline as the comparative group. All three studies randomized their sample population
and matched them to the experimental and control groups. The Shehata et al. study consisted of
20 Egyptian men and women (10 BTX/10 placebo) between the ages of 2772 years of age with
3
a diagnosis of intractable trigeminal neuralgia
. The Wu et al. study consisted of 42 men and

women (22 BTX/20 placebo) between the ages of 3088 year of age with a diagnosis of
4
trigeminal neuralgia
. The Zuniga et al. study consisted of 36 men and women (20 BTX/16
5
placebo) older than 18 years of age with a diagnosis of trigeminal neuralgia
. All of these studies

were 12 weeks in duration. The withdrawal rate of Shehata et al. and Zuniga et al. were 0%,
while Wu et al. had a withdrawal rate of 0.5%. Only one study noted non compliance, Wu et al.,
4
where two participants were withdrawn from the study
.

The results Shehata et al. study showed that the VAS and LOCF results were statistically
significant by participtants having a daily decrease in pain, use of acute medications, paroxysms,
and increase in QoL using Botulinum Toxin A vs. normal saline. These results were shown by
that pain had a decrease by 6.5 with Botulinum Toxin A vs. 0.3 with normal saline, paroxysms
with a score of 0.88 to 7.12 with 95% CI, acute medications with a score of 3.69 to 5.71 with
95% CI, and QoL with a score of 8.35 to 9.65 with 95% CI at the end of 12 weeks, and these all
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had p values of <0.0001 respectively utilizing simple descriptive analysis, ANCOVA model, and
Pearson correlation coefficient. This study also showed adverse effects of facial asymmetry
utilizing ARI and NNH which showed for every 3 participants, 1 participant experienced facial
3
asymmetry
. The results of Wu et al. study showed that the VAS and PGIC showed a statistically

significant decrease in daily pain and daily paroxysms. By utilizing the Fisher exact test, RBI,
ABI, and NNT, PGIC showed for every 3 participants, 1 participant experienced improvement in
daily paroxsyms with a p value of <0.05, and by utilizing the Wilcoxin rank sum test, VAS
showed improvement with daily pain intensity with a score of 1 with the Boltulinum Toxin A vs.
a score of a 5 with the placebo at the end of the 12 weeks which shows a p value <0.05. This
study also showed adverse effects of facial asymmetry utilizing ARI and NNH which showed for
4
every 2 participants, 1 participant experienced facial asymmetry
. The Zuniga et al. showed that

the VAS showed significant decrease in daily pain and paroxysms. Utilizing the Ttest and

paired ttest, VAS showed to be statistically significant by improvement with pain from 4.75 to
6.94 from those treated with Botulinum Toxin A vs. placebo and paroxysms showing a decline
from 29.1 daily to 7.1 with a p value of <0.001 by the end of 12 weeks. This study also showed
adverse effects of facial asymmetry utilizing ARI and NNH which showed for every 10
5
participants, 1 participant experienced facial asymmetry
.
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Table 2 Comparison and statistical significant outcomes measured by included studies
Outcome

Scoring System

Mean scores

pvalue

Statistically significant

pain, paroxysms,

VAS, LOCF,

VAS/LOCF

all

YES, all 95% CI

acute meds, QoL

QoL

Pain 6.5 vs. 0.3

p<0.0001

measured
3
Shehata 2013

Paroxsyms
0.887.12
Acute Meds
3.695.71
QoL 8.35 to 9.65

4
Wu 2012

Pain, paroxysms

VAS, PGIC

Paroxsyms

All P<0.05

YES

VAS

Pain

YES

Pain 4.75 (BTX)

p<0.01

vs. 6.94 (placebo)

Paroxsyms

Paroxsyms

 p<0.001

PGIC= RBI 100%,
ABI 40%, NNT 3
Pain
VAS 1 (BTX) vs.
5 (placebo)
5
Zuniga 2013

Pain, paroxysms

VAS

29.1(beginning) vs.
7.1 (end)
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Table 3: Efficacy of Botulinum Toxin A in the treatment of trigeminal neuralgia
Study

CER

EER

RRI

ARI

NNH

Shehata

0

40%

0

40%

3

0

50%

0

50%

2

5
Zuniga 2013
0

10%

0

10%

10

3
2013
4
Wu 2012

Discussion
After reviewing the results in the studies of this systematic review, several limitations
must be considered when interpreting the results. First of all, different amounts of Botulinum
Toxin A were used in the studies. The placebo visually matched the amount of Botulinum for
each study, but each study used a different amount of Botulinum Toxin A. Secondly, in Shehata
et al., the study only consisted of Egyptian participants, participants had different branches of the
trigeminal nerve affected, and participants were on different medications for pain prior to study
3
and kept on the same regimen throughout the study.
Thirdly, in Wu et al., participants were on

different medications for pain prior to study and kept the same regimen throughout the study, and
4
two participants one from each group withdrew because of lack of efficacy.
Lastly, in Zuniga et

al., participants had different branches of the trigeminal nerve affected, and participants were on
5
different medications for pain prior to study and kept on same regimen throughout the study.

As of now, Botulinum Toxin A is not covered under insurance, but if this problem
continues to rise and affect the general population more and more, it may become FDA approved
and considered to be a treatment option and be covered under insurance in the future.
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Conclusions
All three RCTs have shown that Botulinum Toxin A is safe and effective for the
treatment of trigeminal neuralgia in adults. All three RCTs demonstrated positive outcomes with
Botulinum Toxin A in treating trigeminal neuralgia. The studies showed significant
improvements in daily pain, paroxysms, quality of life, and the use of acute medications. The

studies also showed to have low risk of harmful adverse effects like facial asymmetry. The
participant age, race, sample size, withdrawal rate, study length, and experimental design should
all be considered in future studies. There should be also more research done for Botulinum Toxin
A as a singular treatment instead of adjunctive therapy with oral medications for trigeminal
neuralgia.
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